Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

计划入组 12 人 · 首次发布于 2018 年 11 月 15 日

European Stop Tyrosine Kinase Inhibitor Study

计划入组 868 人 · 首次发布于 2012 年 5 月 10 日

Dysregulated Tyrosine Kinase Signaling in Leukemia

计划入组 30 人 · 首次发布于 2006 年 1 月 13 日

Fostamatinib(Tavalisse, Tavlesse)

C₂₃H₂₆FN₆O₉P · Rx

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Spleen Polypeptide

Rx

Inhibikase Therapeutics

United States

Exelixis, Inc.

United States

Regeneron Pharmaceuticals

United States

TAVALISSE® (Fostamatinib) Approved in Mexico for Chronic ITP Treatment

Rigel's Fostamatinib Enrolls First Patient in Phase I Sickle Cell Disease Trial

Fostamatinib Fails to Improve Outcomes in Hypoxemic COVID-19 Patients